In December 2025, a new antidepressant called Exxua (gepirone extended-release) became commercially available to the American public. To the casual observer, its arrival on pharmacy shelves signaled a triumph of medical innovation—a new tool for the millions of adults struggling with Major Depressive Disorder (MDD). However, beneath the clinical branding lies a regulatory history so contentious that it has reignited a fierce debate over the integrity of the U.S. Food and Drug Administration (FDA) and the standards required to prove a drug is "effective."
The approval of gepirone is not merely a story of a new medication; it is a case study in what critics call "regulatory persistence." Despite failing 11 out of 13 clinical trials, being rejected by the FDA four times over two decades, and receiving a "no" vote from an independent scientific advisory committee, the drug was ultimately granted a green light. The trajectory of gepirone raises fundamental questions about how the FDA defines success and what information doctors are given when they write a prescription.
Main Facts: A Statistical Anomaly
Gepirone, marketed by Fabre-Kramer Pharmaceuticals, is a selective serotonin 5HT1a receptor agonist. Unlike the ubiquitous Selective Serotonin Reuptake Inhibitors (SSRIs) like Prozac or Zoloft, gepirone targets a specific receptor subtype, theoretically offering a different side-effect profile—specifically, a lower risk of weight gain and sexual dysfunction.
However, the primary controversy stems from its efficacy data. Of the 13 short-term and maintenance trials conducted on the drug, only two yielded results that were statistically significant in favor of gepirone over a placebo. In the world of evidence-based medicine, this is an exceptionally low "hit rate."
In a recent exposé published in the top-tier journal JAMA Psychiatry, Dr. Erick H. Turner—a former FDA reviewer and professor emeritus at Oregon Health and Science University—alongside co-authors John H. Powers III, Rosa Y. Ahn-Horst, and Aaron S. Kesselheim, brought this process into the spotlight. Their analysis suggests that the approval of gepirone was less about overwhelming evidence and more about a controversial re-interpretation of "failed" data by high-ranking FDA officials.
Chronology: Four Decades of Rejection and Persistence
The journey of gepirone began in 1986 when it was first synthesized by Bristol-Myers Squibb. By 1993, the company abandoned the drug, selling the rights to Fabre-Kramer. What followed was a 30-year odyssey of regulatory hurdles:
- 1999–2004: Organon (partnering with Fabre-Kramer) submitted a New Drug Application (NDA). The FDA issued a "Refuse to File" letter, citing methodological flaws. A subsequent resubmission in 2001 was met with a "Not Approvable" letter due to a lack of efficacy evidence. By 2004, a third attempt was rejected after the FDA found that the company had manipulated data by reclassifying relapsed patients after the study had been unblinded.
- 2007: After Fabre-Kramer reclaimed full rights, they submitted a fourth NDA including 12 short-term trials and one maintenance trial. The FDA rejected it again, stating the data did not provide sufficient evidence that the drug worked.
- 2015: Following a "Formal Dispute Resolution Request" by the manufacturer, the FDA convened an advisory committee of independent experts. The committee voted 9 to 4 against approval, concluding that the evidence for efficacy was insufficient.
- 2016–2023: Despite the committee’s rejection, John Jenkins, then-Director of the FDA’s Office of New Drugs, issued a letter granting the appeal. He argued that the drug could be approved if more safety data—specifically regarding heart rhythm risks—were provided.
- September 2023: Under the leadership of Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER), the FDA officially approved gepirone.
- December 2025: Exxua enters the commercial market with a price tag of approximately $1,788 per month.
Supporting Data: The "Math" of Approval
The central scientific dispute involves how to interpret a drug that fails the majority of its trials. In the case of gepirone, the FDA’s own experts were highly skeptical.
The Failed Trials
During the review process, Deputy Director Robert Temple noted that in four studies where gepirone was tested against both a placebo and existing antidepressants (like Prozac or Paxil), the existing drugs performed significantly better than gepirone. In several instances, gepirone was not only indistinguishable from the placebo but appeared numerically worse.
Meta-Analysis Manipulation
To overcome the string of negative results, Fabre-Kramer presented a meta-analysis. However, as Turner points out in JAMA Psychiatry, this analysis was highly selective. The company excluded more than half of the failed studies from their calculations. Even with this curated data, the drug only beat the placebo by an average of 1.32 points on the Hamilton Depression Rating Scale (HAMD-17). Most clinicians consider a 2-point difference to be the minimum threshold for "clinical significance"—the point at which a patient might actually feel a difference.
The "False Positive" Risk
FDA statisticians warned that with 13 trials conducted, the two positive results could easily have occurred by pure chance. However, John Jenkins overrode these concerns. He argued that it is "not uncommon" for effective antidepressants to fail to beat placebos in 50% of trials. His logic suggested that since other approved drugs also have high failure rates, gepirone’s failure rate should not be a barrier to its approval.
Official Responses: The FDA’s Internal Divide
The internal documents released by the FDA reveal a stark divide between the agency’s frontline reviewers and its upper management.
The Critics (Robert Temple and the Advisory Committee):
Temple’s 2014 General Advice Letter was scathing. He noted that the "seven negative short-term studies and one negative maintenance trial… raise considerable doubts about the effectiveness of gepirone." He emphasized that the two positive studies were likely "chance findings."
The Proponents (John Jenkins and Janet Woodcock):
Jenkins took a more "permissive" view of the data. He dismissed several failed trials by attributing their failure to "business reasons" rather than the drug’s lack of efficacy. He further argued that even if gepirone were inferior to existing drugs, it could still be approved as long as the label was "appropriate."
Janet Woodcock ultimately supported this stance, moving the drug toward its 2023 approval. The rationale was that providing "more options" for patients outweighed the statistical weakness of the drug’s performance, provided the drug met safety standards.
Implications: The Gap Between Labeling and Reality
The approval of gepirone has profound implications for how medicine is practiced in the United States. Perhaps the most alarming finding in Turner’s report is the discrepancy between the full clinical history of the drug and what appears on the official FDA-approved label.
The Transparency Crisis
The current label for Exxua states that the drug "was evaluated in two eight-week randomized, double-blind, placebo-controlled, flexible-dose studies in adults." It makes no mention of the 11 trials that failed.
This omission is critical because most physicians do not read the primary FDA review documents; they rely on the drug label or point-of-care tools like UpToDate and Micromedex, which are populated using labeling data. "Provided with this information," Turner writes, "clinicians may understandably assume that the drug worked (and was safe) in all trials conducted."
Public Misconception
There is a massive gulf between public perception and regulatory reality. Surveys cited by Turner show that 70% of physicians mistakenly believe the FDA requires a drug to show "clinical significance" (not just statistical significance) for approval. Furthermore, 73% of doctors believe a new drug must be at least as effective as existing treatments. Gepirone fails both of these perceived standards.
Economic Impact
With a projected revenue of $165 million per year by 2029 and a monthly cost exceeding $1,700, Exxua represents a significant financial burden on patients and insurers. If the drug is, as the data suggests, less effective than generic antidepressants that cost a fraction of the price, its commercial success may be driven more by selective marketing than by therapeutic value.
Conclusion: A Call for Reform
The case of gepirone has led to calls for systemic reform within the FDA. Dr. Turner and his colleagues argue for two primary changes:
- Transparent Labeling: The FDA should mandate that product labels include the results of all conducted trials, not just the successful ones. This would allow doctors to see the "hit rate" of a drug and make truly informed decisions.
- Advisory Committee Accountability: Some advocates suggest that the FDA should be legally required to abide by the votes of its independent scientific advisory committees, or at least provide a more rigorous, public justification when they choose to override them.
As Exxua enters the medicine cabinets of thousands of Americans, it serves as a reminder that "FDA Approved" does not always mean a drug is superior, or even comparable, to what is already available. It simply means that, after 30 years of trying, the manufacturer finally found a path through the regulatory maze.
